Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement
- PMID: 15663537
- DOI: 10.1111/j.1526-0968.2004.00183.x
Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement
Abstract
Response to therapeutic plasma exchange (TPE) was evaluated in patients diagnosed with Guillain-Barré Syndrome (GBS). Our aim was to assess response to TPE in patients who had failed treatment with intravenous immune globulin (IVIg). We conducted a retrospective chart review of 10 patients with the diagnosis of Guillain-Barré Syndrome who required TPE. Patients were identified by reviewing data from log books for TPE at The University of Connecticut Health Center, Farmington CT, USA. Patients who had failed IVIg treatment prior to being referred for TPE were also identified. Eight out of 10 patients treated with TPE showed improvement in their neurological exam. Four patients had axonal involvement on electromyelogram (EMG). Three patients were referred for TPE after failing IVIg treatment. All three of these had axonal involvement on EMG. Three of the four patients with axonal involvement demonstrated improvement with TPE. TPE may be a superior treatment option as compared to IVIg in patients with GBS and EMG findings of axonal involvement.
Similar articles
-
Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study.Transfus Apher Sci. 2008 Apr;38(2):109-15. doi: 10.1016/j.transci.2007.11.002. Epub 2008 Mar 10. Transfus Apher Sci. 2008. PMID: 18331814
-
Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.J Clin Neuromuscul Dis. 2010 Dec;12(2):55-61. doi: 10.1097/CND.0b013e3181f3dbbf. J Clin Neuromuscul Dis. 2010. PMID: 21386771
-
Guillain-Barré syndrome in the elderly: clinical, electrophysiological, therapeutic and outcome features.Arq Neuropsiquiatr. 2005 Sep;63(3B):772-5. Epub 2005 Oct 18. Arq Neuropsiquiatr. 2005. PMID: 16258654
-
[Apheresis therapy in Guillain-Barré syndrome].Nihon Rinsho. 2008 Jun;66(6):1195-9. Nihon Rinsho. 2008. PMID: 18540370 Review. Japanese.
-
Treatment of Guillain-Barré syndrome and CIDP.J Peripher Nerv Syst. 2005 Jun;10(2):113-27. doi: 10.1111/j.1085-9489.2005.0010203.x. J Peripher Nerv Syst. 2005. PMID: 15958124 Review.
Cited by
-
Intravenous immunoglobulin and Guillain-Barré syndrome.Clin Rev Allergy Immunol. 2005 Dec;29(3):281-7. doi: 10.1385/CRIAI:29:3:281. Clin Rev Allergy Immunol. 2005. PMID: 16391403
-
Modified Zipper Method, a Promising Treatment Option in Severe Pediatric Immune-Mediated Neurologic Disorders.J Child Neurol. 2022 May;37(6):505-516. doi: 10.1177/08830738221089476. Epub 2022 Apr 18. J Child Neurol. 2022. PMID: 35435761 Free PMC article.
-
Immunoglobulin unresponsive Guillain-Barré syndrome: rinse or repeat? A systematic review.BMJ Neurol Open. 2025 Feb 12;7(1):e000907. doi: 10.1136/bmjno-2024-000907. eCollection 2025. BMJ Neurol Open. 2025. PMID: 39950094 Free PMC article.
-
Therapeutic plasma exchange as a first-choice therapy for axonal Guillain-Barré syndrome: A case-based review of the literature (Review).Exp Ther Med. 2021 Mar;21(3):265. doi: 10.3892/etm.2021.9696. Epub 2021 Jan 25. Exp Ther Med. 2021. PMID: 33603872 Free PMC article. Review.
-
A Case of Paraneoplastic Guillain-Barré Syndrome Associated with Squamous Cell Carcinoma of the Lung.Cureus. 2018 Aug 24;10(8):e3202. doi: 10.7759/cureus.3202. Cureus. 2018. PMID: 30405981 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical